Central venous catheters (CVC) including peripherally inserted central catheters (PICCs) are frequently required for the long-term delivery of therapies, such as lipids, blood transfusions and anti-cancer drugs. CVCs are not without risk, an estimated 250,000 catheter-related blood stream infections occur each year in the USA, with the incidence varying between 0.1 -22.5% depending on the population studied.
1 Such infections increase a patient's risk of death; add to patient's discomfort, cost and length of hospital stay. 2 For example, a case of central line associated blood stream infection (CLABSI) in Australia adds at least AUD $14,000 (2010 dollars) to the cost of care. 3 In the USA, CLABSI accounts for an estimated 28,000 deaths and up to US 2.3 billion annually. 4 There are a number of sources of CLABSI but the most common cause is thought to be the migration of organisms, originating from the patient's skin, along the outer surface of the catheter and into the insertion site. 5 To reduce catheter colonisation, interventions such as central line insertion and maintenance 'care bundles', 3 antimicrobial coatings/impregnation of catheters and equipment 6 An alternate, less expensive product has been recently introduced. It is similar in shape to the CHG disc but instead contains polyhexamethylene biguanide (PHMB), a broadspectrum antimicrobial that is effective up to 7-days (Kendall™ AMD Foam Disc®, Covidien, Basingstoke, UK). The disc has been shown to reduce biofilms in wounds 11 and reduce wound pain and wound size. 12 More importantly, PHMB has been shown to inhibit the growth of Staphylococcus aureus 13 , a common and serious pathogen in CLABSI. To date, there are no randomized controlled trials (RCTs) comparing the effectiveness of the PHMB disc with other products to reduce CLABSI; nor has the CHG disc dressing been tested in head-to-head studies with any other antimicrobial dressing. Consequently, given the burden and cost of CLABSI, the growing cost and prevalence of these products and lack of evidence to show superiority of one product over another, there was an urgent need for an independent, high quality trial to test the safety and efficacy and cost effectiveness of products to prevent CLABSI.
METHODS

Research design
Because no studies of in-vivo use of the PHMB disc have been published, our study aims were to assess i) the safety of the product and ii) the feasibility of conducting a larger, adequately powered trial. We used a single-centre, randomized controlled trial to meet these aims. The trial was prospectively registered on the Australian and New
Zealand Clinical Trials Registry (ANZCTR: 12615000883516; registered 24/8 2015);
we also had approval from the hospital's Human Research Ethics Committee (HREC/15/QRBW/300).
Population and setting
The study hospital is a tertiary referral teaching hospital with over 900 beds, located in South East Queensland, Australia. Non-ICU patients, who were scheduled to have a PICC catheter inserted, were potentially eligible. Inclusion criteria were: i) patients ≥ 18 years of age; ii) requiring a PICC for at least three days; iii) no previous central catheter this admission; and iv) informed consent to participate. Patients were excluded if they: i) had a current bloodstream infection (positive blood culture within 48 hours);
ii) were non-English speakers without an interpreter; iv) had been previously enrolled in the study; or had known allergy to CHG or PHMB.
Data collection
Recruitment and randomization
We designed and conducted the trial in accordance with the standards of The Consolidated Standards of Reporting Trials (CONSORT) Statement. 14 Each week day, a research nurse approached consecutive patients who were scheduled to have a PICC line inserted and provided them with written and oral information about the trial. A person independent of the recruiting nurse prepared a computer generated allocation sequence (1:1 ratio) using randomly varied block sizes of 4 and 8 and no stratification.
Eligible, consenting patients were randomly assigned to one of two groups (CHG disc dressing or PHMB disc) via a telephone service. Allocation was concealed from the recruiting nurse, clinical staff and patients until study entry. Following randomization, blinding was not possible for patients, clinical staff or research staff because the appearance of the discs differed; one product was white and the other had a blue filmtop. However, to eliminate detection bias, the laboratory scientist and the outcome assessor for the clinical outcomes of CLABSI and all cause BSI were blinded to the product used.
Feasibility outcomes:
(i) Eligibility: ≥ 80% of patients screened will be eligible;
(ii) Recruitment: ≥ 80% of eligible participants will agree to enrol;
(iii) Protocol fidelity: ≥ 95% of participants in the intervention group will receive prescribed intervention;
(iv) Retention: < 5% of patients will be lost to follow up.
Clinical outcomes:
(i) Incidence of CLABSI following the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) standardized case definitions. Blood stream infections were considered to be central-lineassociated if the PICC line was in place at the time or within 48 hours before the onset of the infection. 15 The diagnosis was made by a blinded infection control practitioner.
(ii) was assessed in three categories: i) Good' (healthy, well hydrated and elastic); ii) Fair (intact, mildly dehydrated, reduced elasticity); and iii) Poor (papery, dehydrated, small amount or no elasticity). Seven days after hospital discharge; an attempt was made to contact patients by phone or at follow-up clinic to check for any adverse reaction to the study products.
Sample size estimate:
For our feasibility outcomes, based on the method suggested by Hooper, 16 we calculated with a sample of 50 per group we would be able to estimate our noneligibility and inability to recruit rates of 20% to within 95% confidence intervals of +/-4%. This sample size would also be sufficient to estimate our protocol fidelity and loss to follow-up rates of 5% to within 95% confidence intervals of +/-.02%.
Data analysis
Feasibility outcomes were reported descriptively and compared against a priori determined feasibility cut offs of: eligibility 80; recruitment 80%; protocol fidelity > 95%; and retention < 5% lost to follow up. Clinical data from REDcap was imported into SPSS and analysis was performed using the intention-to-treat principle, meaning all patients were analysed in the group to which they were assigned, with the exception of the one randomized patient who did not have a PICC inserted therefore had no outcomes. The sample size was not calculated to test statistical differences between groups so only descriptive data is reported. The CLABSI rate per 1000 inpatient device days was calculated by dividing the number of infections by the number of inpatient device days, multiplied by 1000. by group, are shown in Table 1 .
Results
Between
Feasibility outcomes
next two-day check and the PICC was removed shortly after; as treatment had completed. The total number of device days was 1109 (PHMB 562; CHG 547); resulting in a CLABSI rate per 1000 catheter days of 1.8 (PHMB 1.8; CHG 1,8).
Discussion
The primary goal of this study was to examine a number of feasibility outcomes while also collecting safety and clinical data. The main preclusions eligibility were unavoidable, being patients too unwell to approach for consent, or having their PICC insertion cancelled. While this 70% eligibility of screened patients was lower than our target of 80%, this had very little impact on the study feasibility. The time spent on screening was minimal, with the majority of patients being excluded simply by checking computer lists. This screening could be achieved between patient recruitment or while waiting for new patients to arrive at the medical imaging unit.
The important outcomes of recruitment and retention were easily met. Only 3.5% of patients declined to consent and retention was 100% so we demonstrated an ability to follow patients until their hospital discharge.
The target for protocol fidelity was met in that 98% of patients received the allocated intervention at study entry. However the incidence of partial violations was much higher with the majority of violations involving clinical nurses (not research staff)
incorrectly replacing PHMB discs with a CHG disc at a dressing change. Despite several methods to identify group allocation (stickers on the patients medical record; their day care plan; and on the dressing), errors occurred. CHG was standard care, so the process is entrenched and the product easily accessable. The fidelity problem was identified early in the trial and largely resolved after a further series of information sessions and storage of the allocated study product in the patient's bedside. Of course French; no triple lumen catheters were used in the study Caption for figure Figure 1 . Flow of participants
